VIROBLOCK SA specialises in the discovery and development of a brand new generation of antiviral products with a novel mechanism of action against enveloped viruses, which include major human pathogens such as human and avian influenzas, SARS virus and the AIDS virus.
Employees: 1-10
Total raised: $836.68K
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | BlueOcean ... | blueocean-... |
| - | Fongit See... | fongitseed... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.02.2012 | Series C | $836.68K | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.06.2013 | Viroblock launches anti-viral face mask | |
| 04.01.2013 | Viroblock announces launch of its respiratory mask | |
| 28.02.2012 | Viroblock Raises CHF750K in Final Close of Series C Financing Round | Viroblock S.A., a Switzerland-based anti-viral company, has held a CHF750k second and final closing of its Series C financing round, which initially closed in October 2011 (read here). This additional investment, from a small group of angel... |
| 28.10.2011 | Viroblock closes Series C financing round | |
| 02.12.2010 | CTI Start-up Label |